

**IN THE SPECIFICATION**

Please enter the amendments to the specification below.

**Cross-Reference to Related Applications**

This application claims priority to International Application PCT/US 97/09099, filed May 30, 1997, Provisional Application, Serial No., 60/018,773, filed May 31, 1996, Provisional Application, Serial No., 60/015,869, filed May 31, 1996, International Application PCT/US96/13194, filed August 13, 1996, now abandoned, and U.S. application, Serial No., 08/514,799, filed August 14, 1995, now abandoned.

**IN THE CLAIMS**

Please cancel claims 49-59, and 63.

Please enter the amended claims below, the amendments of which are provided in Appendix I.

60. (Amended) A method for inhibiting  $\alpha_v\beta_5$  mediated angiogenesis in a tissue comprising administering to said tissue a composition comprising an angiogenesis-inhibiting amount of an  $\alpha_v\beta_5$  antagonist.

F 61. (Amended) The method of claim 60 wherein said antagonist is a matrix metalloproteinase polypeptide that includes an amino acid residue sequence shown in SEQ ID NO 11, 12, 13, 14, 15, 15, 17, 19, 20, 21 or 22.